Einzeltreffer — DigiBib

This document provides methods and materials involved in treating congenital disorders of glycosylation (CDGs). For example, methods for using a composition including one or more uridine diphosphate (UDP)—sugars to treat a mammal (e.g., a human) having a CDG are provided.

Titel:	METHODS AND MATERIALS FOR TREATING GLYCOSYLATION DISORDERS
Link:	View record in USPTO Patent Applications (Volltext)
Veröffentlichung:	2022
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20220241311 Publication Date: August 4, 2022 Appl. No: 16/973210 Application Filed: June 14, 2019 Claim: 1. A method for treating a mammal having a congenital disorder of glycosylation (CDG), wherein said method comprises administering a composition comprising UDP-galactose and UDP-glucose to said mammal. Claim: 2. The method of claim 1, wherein said mammal is a human. Claim: 3. The method of claim 1, wherein said CDG is phosphoglucomutase 1 CDG (PGM1-CDG). Claim: 4. The method of claim 1, wherein a ratio of UDP-galactose to UDP-glucose is from about 1:1 to about 10:1. Claim: 5. The method of claim 4, wherein a ratio of UDP-galactose to UDP-glucose is 3:1. Claim: 6. The method of claim 1, wherein administering said composition results in said mammal having a blood concentration of UDP-galactose of from about 5 μM to about 50 μM. Claim: 7. The method of claim 1, wherein administering said composition results in said mammal having a blood concentration of UDP-glucose of from about 2 μM to about 20 μM. Claim: 8. The method of claim 1, wherein said treatment is effective to reduce one or more symptoms of said CDG. Claim: 9. The method of claim 1, wherein said treatment is effective to restore glycosylation in said mammal. Claim: 10. A method for restoring glycosylation in a mammal having a congenital disorder of glycosylation (CDG), wherein said method comprises administering a composition comprising UDP-galactose and UDP-glucose to said mammal. Claim: 11. The method of claim 10, wherein said mammal is a human. Claim: 12. The method of claim 10, wherein said CDG is phosphoglucomutase 1 CDG (PGM1-CDG). Claim: 13. The method of claim 10, wherein a ratio of UDP-galactose to UDP-glucose is from about 1:1 to about 10:1. Claim: 14. The method of claim 13, wherein a ratio of UDP-galactose to UDP-glucose is 3:1. Claim: 15. The method of claim 10, wherein administering said composition results in said mammal having a blood concentration of UDP-galactose of from about 5 μM to about 50 μM. Claim: 16. The method of claim 10, wherein administering said composition results in said mammal having a blood concentration of UDP-glucose of from about 2 μM to about 20 μM. Claim: 17. The method of claim 10, wherein said restored glycosylation is assessed using a ratio of a reduced transferrin glycosylation form over a normal transferrin glycosylation form, and wherein a decreased ratio indicates restored glycosylation. Claim: 18. The method of claim 10, wherein said restored glycosylation is assessed using a level of one or more liver enzymes within said mammal, wherein a decreased level of one or more liver enzymes indicates restored glycosylation, and wherein said one or more liver enzymes are selected from the group consisting of aspartate transaminase (AST) and alanine transaminase (ALT). Claim: 19. The method of claim 10, wherein said restored glycosylation is assessed using a level of one or more coagulation factors within said mammal, wherein a decreased level of one or more coagulation factors indicates restored glycosylation, and wherein said one or more coagulation factors comprise activated prothrombin time (aPTT). Claim: 20. The method of claim 10, wherein said restored glycosylation is assessed using a level of one or more coagulation factors within said mammal, wherein an increased level of one or more coagulation factors indicates restored glycosylation, and wherein said one or more coagulation factors are selected from the group consisting of anti-thrombin III (ATIII), Factor XI, and Factor XIII. Current International Class: 61; 61

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

METHODS AND MATERIALS FOR TREATING GLYCOSYLATION DISORDERS